<code id='6E6D351C6A'></code><style id='6E6D351C6A'></style>
    • <acronym id='6E6D351C6A'></acronym>
      <center id='6E6D351C6A'><center id='6E6D351C6A'><tfoot id='6E6D351C6A'></tfoot></center><abbr id='6E6D351C6A'><dir id='6E6D351C6A'><tfoot id='6E6D351C6A'></tfoot><noframes id='6E6D351C6A'>

    • <optgroup id='6E6D351C6A'><strike id='6E6D351C6A'><sup id='6E6D351C6A'></sup></strike><code id='6E6D351C6A'></code></optgroup>
        1. <b id='6E6D351C6A'><label id='6E6D351C6A'><select id='6E6D351C6A'><dt id='6E6D351C6A'><span id='6E6D351C6A'></span></dt></select></label></b><u id='6E6D351C6A'></u>
          <i id='6E6D351C6A'><strike id='6E6D351C6A'><tt id='6E6D351C6A'><pre id='6E6D351C6A'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:91351
          Adam's take main illustration
          Molly Ferguson/STAT

          This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

          A Worst CEO gets some much-needed help

          For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

          advertisement

          On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Trump demands the U.S. pay no more for drugs than other countries … again
          Trump demands the U.S. pay no more for drugs than other countries … again

          EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

          read more
          Anger, defiance, fear over Supreme Court decision to block student loan forgiveness
          Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

          PeopleinfavorofcancelingstudentdebtprotestoutsidetheSupremeCourt,June30,2023,asdecisionsareexpectedi

          read more
          Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
          Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

          FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

          read more

          Hospital price transparency does save money, advocate argues

          CynthiaFisher,founderandchairman,PatientRightsAdvocate.orgSTATBOSTON—Forallthosewhothinkhospitalpric